PSA Doubling Time (PSADT) Calculator
Calculates rate of PSA doubling in prostate cancer (correlates with survival).
114 entries · Page 4 of 4
Calculates rate of PSA doubling in prostate cancer (correlates with survival).
Predicts 30-day outcome of patients with pulmonary embolism.
Stages chronic lymphocytic leukemia, similar to Binet Staging System .
Estimates number of donor RBC units to screen to obtain a desired number of antigen-negative units.
Estimates risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B.
Categorizes renal masses by complexity for surgical decision-making.
Prognostication tool for myeloma patients based on the genetics and other routinely used lab values in conjunction with the original ISS Staging System.
Determine the risk of major bleeding during anticoagulant therapy.
Predicts risk that an adnexal mass is malignant.
Estimates the volume of donor RBCs needed for RBC exchange in patients with sickle cell disease.
Predicts 30-day outcome of patients with PE, with fewer criteria than the original PESI.
Predicts survival of CML based on clinical and lab information.
Predicts malignancy risk in solitary lung nodules on chest x-ray.
Predicts progression of clear cell renal cell carcinoma after radical nephrectomy.
Converts steroid dosages using dosing equivalencies.
Predicts the need for massive transfusion based on clinical and laboratory data.
Estimates amount of a substance (e.g. antibody) remaining in the intravascular space after a given number of plasma volume exchanges.
Provides 5-year disease-free prognosis for localized and metastatic RCC.
Predicts outcomes of patients post-treatment for prostate cancer.
Stratifies severity of post-thrombotic syndrome in lower extremity DVT.
Evaluates prognosis of patients with myelodysplastic syndrome (MDS).
No entries match your filter.